{"id":"meningococcal-vaccine","safety":{"commonSideEffects":[{"rate":"20–50","effect":"Injection site pain, erythema, or swelling"},{"rate":"5–15","effect":"Fever"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Myalgia or fatigue"},{"rate":"2–5","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2109142","moleculeType":"Vaccine component"},"_dailymed":{"setId":"fd5652b6-5ae4-437e-a456-47deaf500794","title":"PENBRAYA (MENINGOCOCCAL GROUPS A, B, C, W, AND Y VACCINE) KIT [PFIZER LABORATORIES DIV PFIZER INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meningococcal vaccines contain antigens derived from the bacterial capsule or outer membrane proteins of Neisseria meningitidis. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells. This immune priming enables rapid recognition and neutralization of the pathogen upon natural exposure, preventing invasive meningococcal disease including meningitis and septicemia.","oneSentence":"The meningococcal vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis, preventing meningococcal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:21.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"},{"name":"Prevention of invasive meningococcal disease in infants, children, adolescents, and adults"}]},"trialDetails":[{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT05935176","phase":"PHASE4","title":"Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-20","conditions":"Epidemic Meningitis","enrollment":660},{"nctId":"NCT07135986","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-26","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":1602},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT04704830","phase":"PHASE3","title":"R21/Matrix-M in African Children Against Clinical Malaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2021-04-29","conditions":"Malaria","enrollment":4800},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT07395739","phase":"PHASE1","title":"A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)","startDate":"2026-02-24","conditions":"Neisseria Meningitidis Serogroup B","enrollment":30},{"nctId":"NCT07379151","phase":"","title":"Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2026-03","conditions":"Meningoccocal Disease","enrollment":450},{"nctId":"NCT07374510","phase":"PHASE1","title":"Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2026-01-21","conditions":"Meningococcal Meningitis","enrollment":150},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06832514","phase":"PHASE4","title":"Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons","status":"RECRUITING","sponsor":"University Ghent","startDate":"2025-01-31","conditions":"Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response","enrollment":250},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT06834100","phase":"PHASE3","title":"Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug","status":"RECRUITING","sponsor":"NPO Petrovax","startDate":"2025-02-12","conditions":"Infections, Meningococcal","enrollment":240},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT06284915","phase":"PHASE3","title":"Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-03-19","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":840},{"nctId":"NCT04843111","phase":"","title":"Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)","status":"RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-05","conditions":"Meningococcal Infection","enrollment":50},{"nctId":"NCT07204457","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old","status":"RECRUITING","sponsor":"EyeGene Inc.","startDate":"2025-10-15","conditions":"Meningococcal Infections","enrollment":1123},{"nctId":"NCT07252804","phase":"PHASE4","title":"Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-01","conditions":"Autoimmune Rheumatologic Disease","enrollment":263},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT06995430","phase":"PHASE3","title":"A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-07-07","conditions":"Meningitis","enrollment":226},{"nctId":"NCT04166656","phase":"PHASE3","title":"Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-15","conditions":"Splenectomy","enrollment":84},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT05929651","phase":"PHASE4","title":"Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-09-07","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":71},{"nctId":"NCT06228586","phase":"PHASE3","title":"Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-01-18","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":447},{"nctId":"NCT04368429","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-22","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":360},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT03890367","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-12","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":707},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04142242","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-04","conditions":"Meningococcal Infection (Healthy Volunteers)","enrollment":471},{"nctId":"NCT04400838","phase":"PHASE2, PHASE3","title":"Investigating a Vaccine Against COVID-19","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-05-28","conditions":"Coronavirus","enrollment":10811},{"nctId":"NCT06389513","phase":"PHASE4","title":"Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-06-12","conditions":"Epidemic Meningitis","enrollment":3011},{"nctId":"NCT05087056","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-11-18","conditions":"Meningitis, Meningococcal","enrollment":302},{"nctId":"NCT06113198","phase":"PHASE4","title":"A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-11-10","conditions":"Meningitis, Meningococcal","enrollment":50},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06700148","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-14","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06226714","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-01","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06446752","phase":"PHASE3","title":"BIYELA - Bexsero Immunisation in Young Women in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-08-14","conditions":"Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus","enrollment":1100},{"nctId":"NCT04936685","phase":"PHASE3","title":"Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-08-23","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":209},{"nctId":"NCT06011200","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-16","conditions":"Epidemic Meningitis","enrollment":1000},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT03299426","phase":"PHASE3","title":"Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-21","conditions":"Typhoid","enrollment":30000},{"nctId":"NCT03295318","phase":"PHASE2","title":"Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-11-15","conditions":"Meningitis, Meningococcal","enrollment":375},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT06906692","phase":"","title":"Meningococcal Vaccination in Patients on Complement Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-03-25","conditions":"Myasthenia Gravis Generalised, Vaccination, Complement System","enrollment":35},{"nctId":"NCT04415424","phase":"PHASE3","title":"Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2021-07-08","conditions":"Neisseria Gonorrheae Infection","enrollment":650},{"nctId":"NCT03869866","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-04-09","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":290},{"nctId":"NCT03562377","phase":"PHASE2","title":"Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-07-13","conditions":"Atopic Dermatitis","enrollment":215},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT04318548","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-25","conditions":"Infections, Meningococcal","enrollment":945},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT04143061","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-12-30","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":1328},{"nctId":"NCT04440176","phase":"PHASE2","title":"A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":309},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT06025487","phase":"PHASE2","title":"Meningococcal B Vaccine in Patients with Asplenia","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-03-12","conditions":"Splenectomy; Status","enrollment":80},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Gonorrhoea","enrollment":52},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT04893811","phase":"PHASE4","title":"Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-18","conditions":"Meningococcal Vaccine","enrollment":53},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT02294487","phase":"","title":"Study of the Immune Response After Vaccination in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-12-30","conditions":"Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple","enrollment":19},{"nctId":"NCT01967238","phase":"EARLY_PHASE1","title":"An Open Label Study of IgG Fc Glycan Composition in Human Immunity","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2013-03","conditions":"Healthy","enrollment":129},{"nctId":"NCT04597424","phase":"PHASE3","title":"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-01-19","conditions":"Unsafe Sex, Risk-Taking","enrollment":556},{"nctId":"NCT04707391","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-25","conditions":"Meningitis, Meningococcal","enrollment":1250},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314880","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-07-22","conditions":"Healthy Volunteers","enrollment":300},{"nctId":"NCT06314659","phase":"PHASE3","title":"Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-17","conditions":"Healthy Population","enrollment":630},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT06337071","phase":"PHASE2","title":"A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1200},{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06209398","phase":"PHASE4","title":"Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2018-05-24","conditions":"Hand, Foot and Mouth Disease","enrollment":510},{"nctId":"NCT05739292","phase":"PHASE1","title":"Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2023-02-28","conditions":"Infection, Meningococcal","enrollment":60},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT06165276","phase":"PHASE1","title":"A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07-25","conditions":"Meningococcal Immunization","enrollment":285},{"nctId":"NCT01640652","phase":"PHASE1","title":"MenPF-1 - A New Vaccine Against Meningococcal Disease","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-08","conditions":"Serogroup B Meningococcal Disease","enrollment":52},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT04450498","phase":"PHASE4","title":"A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2020-12-23","conditions":"Neisseria Meningitides Meningitis","enrollment":260},{"nctId":"NCT01725217","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-11","conditions":"Meningococcal Disease","enrollment":198},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT01693380","phase":"PHASE4","title":"Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2009-05","conditions":"Influenza, Acute Respiratory Infection","enrollment":1742},{"nctId":"NCT04224311","phase":"PHASE4","title":"Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-03-12","conditions":"Preventive Immunization; Meningitis","enrollment":102},{"nctId":"NCT05298644","phase":"PHASE2, PHASE3","title":"COVID-19 Paediatric VLA2001-321 Study","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2022-10-01","conditions":"SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT02868541","phase":"","title":"Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims.","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-25","conditions":"Acute Respiratory Infection","enrollment":905},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":979,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Meningitec, NeisVacC, Menitorix, Menveo, Nimenrix","Menomune"],"phase":"marketed","status":"active","brandName":"Meningococcal (vaccine)","genericName":"Meningococcal (vaccine)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"The meningococcal vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis, preventing meningococcal disease. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y, Prevention of meningococcal meningitis and septicemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}